Navigation Links
Telik Announces Telintra Clinical Presentations at the Annual Meeting of the American Society of Hematology
Date:11/10/2011

PALO ALTO, Calif., Nov. 10, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) announced today two clinical presentations at the 53rd Annual Meeting of the American Society of Hematology in San Diego, California. Details of the presentations are as follows:

  • Phase 1 Dose-Ranging Study of Oral Ezatiostat Hydrochloride (Telintra®, TLK199) in Combination with Lenalidomide (Revlimid®) in Patients with Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS); Azra Raza, MD; Naomi Galili, PhD; Deborah Mulford, MD; Scott E. Smith, MD, PhD, FACP; Gail Brown, MD; Lisa Meng, PhD; David P. Steensma, MD; Roger M Lyons, MD; Ralph Boccia, MD; Mikkael A. Sekeres, MD, MS; Guillermo Garcia-Manero, MD; and Ruben A. Mesa, MD
    • Abstract #2778 – Myelodysplastic Syndromes: Poster II; Sunday, December 11, 2011, 6:00 PM -8:00 PM; San Diego Convention Center, Hall GH
  • Gene Expression Studies May Identify Lower Risk Myelodysplastic Syndrome Patients Likely to Respond to Therapy with Ezatiostat Hydrochloride (TLK199); Naomi Galili, Ph.D.; Pablo Tamayo, PhD; Olga B Botvinnik; Jill P Mesirov, PhD; Jennifer Zikria, MD; Gail Brown, MD and Azra Raza, MD
    • Abstract #2779 – Myelodysplastic Syndromes: Poster II; Sunday, December 11, 2011, 6:00 PM - 8:00 PM; San Diego Convention Center, Hall GH

About Telik

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer. The company's most advanced drug candidate is Telintra®, a modified glutathione analog intended for the treatment of hematologic malignancies including myelodysplastic syndrome; followed by Telcyta®, a cancer activated prodrug for the treatment of a variety of cancers. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.

Telik, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.


'/>"/>
SOURCE Telik, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Telik Announces Third Quarter 2011 Financial Results
2. Telik Announces Publication of a Report of Complete Response of G-CSF Resistent Severe Idiopathic Chronic Neutropenia Following Treatment with Telintra®
3. Telik Announces Ezatiostat (Telintra®) Preclinical Presentation at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
4. Telik Announces Initiation of a Phase 2b Clinical Trial of Telintra® (Ezatiostat HCL) in Patients With Low to Intermediate-1 Risk Non-Deletion (5q) Myelodysplastic Syndrome
5. Telik Announces Publication in the Journal Cancer of a Phase 2 Randomized Multicenter Study of Two Extended Dosing Schedules of Oral Ezatiostat in Low to Intermediate-1 Risk Myelodysplastic Syndrome
6. Telik Announces First Quarter 2011 Financial Results
7. Telik Announces Presentation of New Data on the Characterization of Novel Ezatiostat (TELINTRA®, TLK199) Analogs at American Association for Cancer Research Annual Meeting
8. Telik Announces Presentation and Webcast at 10th Annual Needham Healthcare Conference
9. Telik Announces Fourth Quarter and 2010 Year End Financial Results and 2011 Financial Guidance
10. Telik Announces Presentation and Webcast at 13th Annual BIO CEO & Investor Conference
11. Telik Announces Presentation at American Society of Hematology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... Research and Markets has ... Myeloma Market and Competitive Landscape Highlights - ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ... Highlights 2016, provides comprehensive insights into Multiple ... Myeloma market valuations and forecast, Multiple Myeloma ...
(Date:5/4/2016)... Research and Markets has ... Ischemic Stroke Market and Competitive Landscape Highlights ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ... Market and Competitive Landscape Highlights 2016, provides ... products, Acute Ischemic Stroke epidemiology, Acute Ischemic ...
(Date:5/4/2016)... 4, 2016 Research ... "Global Acute Myeloid Leukemia Market and Competitive ... offering.       (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Market and Competitive Landscape Highlights 2016, provides ... products, Acute Myeloid Leukemia epidemiology, Acute Myeloid ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... May 04, 2016 , ... The preeminent surgical aftercare facility Pearl ... following breast cancer surgery. In March 2016, the 61-year-old model and reality TV star ... that occurs in the milk ducts, according to an interview with the Daily ...
(Date:5/4/2016)... ... 2016 , ... Warren L. Smith M.D. , There is a new tool ... people since the beginning of recorded medical history, and in spite of all the ... just a matter of inconvenience; bladder infections cost us billions of dollars annually in ...
(Date:5/4/2016)... ... May 04, 2016 , ... Over 40 athletic trainer’s (ATs) and athletic ... for the annual “Hike to Harrisburg” advocacy day. The annual lobbying effort is ... lobby Group. The goal for the day was to educate the elected legislators ...
(Date:5/3/2016)... ... May 04, 2016 , ... ... and global construction firms representing the Construction Industry Safety Initiative (CISI) and the ... one purpose: to inspire everyone in the industry to be leaders in safety. ...
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... In April, ... with today’s latest technologies to help find the best steam and sauna solutions. , ... device, using responsive design. This improvement brings all of the site’s features, especially the ...
Breaking Medicine News(10 mins):